115 related articles for article (PubMed ID: 12678175)
1. Correlation between Doppler vascular density and PSA response to radiation therapy in patients with localized prostate carcinoma.
Sehgal CM; Arger PH; Holzer AC; Krisch RE
Acad Radiol; 2003 Apr; 10(4):366-72. PubMed ID: 12678175
[TBL] [Abstract][Full Text] [Related]
2. Predicting PSA response of prostate cancer to radiation therapy with Doppler sonography.
Krisch RE; Sehgal CM; Arger PH
J Clin Ultrasound; 2007 Oct; 35(8):442-8. PubMed ID: 17506081
[TBL] [Abstract][Full Text] [Related]
3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
[TBL] [Abstract][Full Text] [Related]
6. Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate.
McLean M; Panzarella T; Warde PR; Gospodarowicz M; Duncan W; Catton C; Bissett R
Clin Oncol (R Coll Radiol); 1997; 9(4):226-33. PubMed ID: 9315396
[TBL] [Abstract][Full Text] [Related]
7. Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers.
Kuligowska E; Barish MA; Fenlon HM; Blake M
Radiology; 2001 Sep; 220(3):757-64. PubMed ID: 11526279
[TBL] [Abstract][Full Text] [Related]
8. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
Kaminski JM; Hanlon AL; Horwitz EM; Pinover WH; Mitra RK; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):888-92. PubMed ID: 11958880
[TBL] [Abstract][Full Text] [Related]
9. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
Pollack A; Lankford S; Zagars GK; Babaian RJ
Cancer; 1996 Apr; 77(8):1515-23. PubMed ID: 8608537
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
Zagars GK; Pollack A
Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
[TBL] [Abstract][Full Text] [Related]
14. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival.
Ismail M; Petersen RO; Alexander AA; Newschaffer C; Gomella LG
Urology; 1997 Dec; 50(6):906-12. PubMed ID: 9426722
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
16. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
17. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
Zagars GK; Pollack A
Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
[TBL] [Abstract][Full Text] [Related]
18. Color and power Doppler sonography in the diagnosis of prostate cancer: comparison between vascular density and total vascularity.
Arger PH; Malkowicz SB; VanArsdalen KN; Sehgal CM; Holzer A; Schultz SM
J Ultrasound Med; 2004 May; 23(5):623-30. PubMed ID: 15154528
[TBL] [Abstract][Full Text] [Related]
19. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
